The experimental drug olaparib (AstraZeneca) appears like a promising treatment for a wide array of ovarian cancers, not just those associated with BRCA1 and BRCA2 it is partially mutations, according to an alternative study published online right now in Lancet Oncology.”To the most effective of our knowledge, this can be a first study demonstrating activity
(Read More…)




